Business Standard

Reducing dose gap may help liquidate Covishield vaccine stocks faster

Liquidating stocks is critical for SII as it can store around 600-700 million doses at its site.

India too had opened diplomatic dialogues with the European Union (EU) after the EU Digital Covid Certificate framework recognised the AstraZeneca-Oxford vaccine, but not Covishield.
Premium

Sohini Das Mumbai
The Centre’s recent move to reduce the gap between two Covishield doses to 8-16 weeks from the earlier gap of 12-16 weeks may help liquidate vaccine stocks faster.

Covishield maker Serum Institute of India (SII) is sitting on 200-250 million doses of the vaccine at its Pune facility. The administration of Covishield at a reduced gap of 8 weeks has not started yet.

However, this would create a faster turnaround of stocks lying with the government and private hospitals, thereby leading to a liquidation of the inve­ntory lying with the company.

A source close to the developments told Business Standard

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 24 2022 | 6:04 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com